643 related articles for article (PubMed ID: 25738220)
1. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.
Sholl LM; Aisner DL; Varella-Garcia M; Berry LD; Dias-Santagata D; Wistuba II; Chen H; Fujimoto J; Kugler K; Franklin WA; Iafrate AJ; Ladanyi M; Kris MG; Johnson BE; Bunn PA; Minna JD; Kwiatkowski DJ;
J Thorac Oncol; 2015 May; 10(5):768-777. PubMed ID: 25738220
[TBL] [Abstract][Full Text] [Related]
2. Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
Steuer CE; Behera M; Berry L; Kim S; Rossi M; Sica G; Owonikoko TK; Johnson BE; Kris MG; Bunn PA; Khuri FR; Garon EB; Ramalingam SS
Cancer; 2016 Mar; 122(5):766-72. PubMed ID: 26695526
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
[TBL] [Abstract][Full Text] [Related]
4. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT
J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512
[TBL] [Abstract][Full Text] [Related]
5. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
6. High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.
Wu C; Zhao C; Yang Y; He Y; Hou L; Li X; Gao G; Shi J; Ren S; Chu H; Zhou C; Zhang J; Schmid-Bindert G
J Thorac Oncol; 2015 May; 10(5):778-783. PubMed ID: 25629635
[TBL] [Abstract][Full Text] [Related]
7. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
Chen LF; Chen XY; Yu XB
Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
[TBL] [Abstract][Full Text] [Related]
8. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
[TBL] [Abstract][Full Text] [Related]
9. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Chaft JE; Arcila ME; Paik PK; Lau C; Riely GJ; Pietanza MC; Zakowski MF; Rusch V; Sima CS; Ladanyi M; Kris MG
Mol Cancer Ther; 2012 Feb; 11(2):485-91. PubMed ID: 22135231
[TBL] [Abstract][Full Text] [Related]
10. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
Wang R; Pan Y; Li C; Zhang H; Garfield D; Li Y; Ye T; Hu H; Luo X; Li H; Zhang Y; Zhang J; Zhou X; Shen L; Pao W; Sun Y; Chen H
J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
[TBL] [Abstract][Full Text] [Related]
11. Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.
Cassidy RJ; Zhang X; Patel PR; Shelton JW; Escott CE; Sica GL; Rossi MR; Hill CE; Steuer CE; Pillai RN; Ramalingam SS; Owonikoko TK; Behera M; Force SD; Fernandez FG; Curran WJ; Higgins KA
Cancer; 2017 Oct; 123(19):3681-3690. PubMed ID: 28608966
[TBL] [Abstract][Full Text] [Related]
12. Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.
Xia N; An J; Jiang QQ; Li M; Tan J; Hu CP
Exp Lung Res; 2013 Oct; 39(8):328-35. PubMed ID: 23919423
[TBL] [Abstract][Full Text] [Related]
13. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
14. Assessment of intratumoral heterogeneity of oncogenic driver mutations in surgically-resected lung adenocarcinoma: implications of percutaneous biopsy-based molecular assay for target-directed therapy.
Kim HK; Lee HY; Choi YL; Choi SJ; Choi H; Lee J; Han J; Ahn MJ; Lee KS; Kim J
Anticancer Res; 2014 Feb; 34(2):707-14. PubMed ID: 24511003
[TBL] [Abstract][Full Text] [Related]
15. Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.
Ohba T; Toyokawa G; Osoegawa A; Hirai F; Yamaguchi M; Taguchi K; Seto T; Takenoyama M; Ichinose Y; Sugio K
Surg Today; 2016 Sep; 46(9):1091-8. PubMed ID: 26711128
[TBL] [Abstract][Full Text] [Related]
16. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.
Zhang Y; Sun Y; Pan Y; Li C; Shen L; Li Y; Luo X; Ye T; Wang R; Hu H; Li H; Wang L; Pao W; Chen H
Clin Cancer Res; 2012 Apr; 18(7):1947-53. PubMed ID: 22317764
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Mutation Profiling and Validation of Non-Small-Cell Lung Cancer Small Biopsy Samples using a High Throughput Platform.
Quinn AM; Hickson N; Adaway M; Priest L; Jaeger E; Udar N; Keeling C; Kamieniorz M; Dive C; Wallace A; Byers RJ; Newman WG; Nonaka D; Blackhall FH
J Thorac Oncol; 2015 May; 10(5):784-792. PubMed ID: 25634010
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
Grosse A; Grosse C; Rechsteiner M; Soltermann A
Diagn Pathol; 2019 Feb; 14(1):18. PubMed ID: 30744664
[TBL] [Abstract][Full Text] [Related]
19. Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.
Martín Martorell P; Huerta M; Compañ Quilis A; Abellán R; Seda E; Blesa S; Chaves FJ; Dualde Beltrán D; Roselló Keränen S; Franco J; Insa A
Clin Lung Cancer; 2017 Nov; 18(6):e395-e402. PubMed ID: 28550959
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status.
Wang J; Dong Y; Cai Y; Zhou L; Wu S; Liu G; Su D; Li X; Qin N; Nong J; Jia H; Zhang Q; Mu J; Zeng X; Zhang H; Zhang S; Zhang Z
J Cancer Res Clin Oncol; 2014 Mar; 140(3):453-60. PubMed ID: 24442099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]